PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Heinrich, K.* ; Miller-Phillips, L.* ; Ziemann, F.* ; Hasselmann, K.* ; Rühlmann, K.* ; Flach, M.* ; Biro, D.* ; von Bergwelt-Baildon, M.* ; Holch, J.* ; Herold, T.* ; von Baumgarten, L.* ; Greif, P.A.* ; Jeremias, I. ; Wuerstlein, R.* ; Casuscelli, J.* ; Spitzweg, C.* ; Seidensticker, M.* ; Renz, B.* ; Corradini, S.* ; Baumeister, P.* ; Goni, E.* ; Tufman, A.* ; Jung, A.* ; Kumbrink, J.* ; Kirchner, T.* ; Klauschen, F.* ; Metzeler, K.H.* ; Heinemann, V.* ; Westphalen, C.B.*

Lessons learned: The first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board.

J. Cancer Res. Clin. Oncol., DOI: 10.1007/s00432-022-04165-0 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
PURPOSE: In 2016, the University of Munich Molecular Tumor Board (MTB) was implemented to initiate a precision oncology program. This review of cases was conducted to assess clinical implications and functionality of the program, to identify current limitations and to inform future directions of these efforts. METHODS: Charts, molecular profiles, and tumor board decisions of the first 1000 consecutive cases (01/2016-03/2020) were reviewed. Descriptive statistics were applied to describe relevant findings. RESULTS: Of the first 1000 patients presented to the MTB; 914 patients received comprehensive genomic profiling. Median age of patients was 56 years and 58% were female. The most prevalent diagnoses were breast (16%) and colorectal cancer (10%). Different types of targeted or genome-wide sequencing assays were used; most of them offered by the local department of pathology. Testing was technically successful in 88%. In 41% of cases, a genomic alteration triggered a therapeutic recommendation. The fraction of patients receiving a tumor board recommendation differed significantly between malignancies ranging from over 50% in breast or biliary tract to less than 30% in pancreatic cancers. Based on a retrospective chart review, 17% of patients with an MTB recommendation received appropriate treatment. CONCLUSION: Based on these retrospective analyses, patients with certain malignancies (breast and biliary tract cancer) tend to be more likely to have actionable variants. The low rate of therapeutic implementation (17% of patients receiving a tumor board recommendation) underscores the importance of meticulous follow-up for these patients and ensuring broad access to innovative therapies for patients receiving molecular tumor profiling.
Impact Factor
Scopus SNIP
Altmetric
4.322
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Comprehensive Genomic Profiling ; Molecular Tumor Board ; Personalized Medicine ; Precision Oncology ; Targeted Therapy
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0171-5216
e-ISSN 1432-1335
Zeitschrift Journal of Cancer Research and Clinical Oncology
Verlag Springer
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
POF Topic(s) 30204 - Cell Programming and Repair
Forschungsfeld(er) Stem Cell and Neuroscience
PSP-Element(e) G-506600-001
Förderungen Projekt DEAL
DOI 10.1007/s00432-022-04165-0
WOS ID WOS:000825374300001
Scopus ID 85133558809
PubMed ID 35796778
Erfassungsdatum 2022-10-31
[➜Korrektur melden]